Anu Jacob

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10985890/publications.pdf

Version: 2024-02-01

92 papers	10,164 citations	61984 43 h-index	45317 90 g-index
94 all docs	94 docs citations	94 times ranked	5929 citing authors

#	Article	IF	Citations
1	Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Associated Disease in the United Kingdom. JAMA Network Open, 2022, 5, e2142780.	5.9	46
2	Health utilities and costs for neuromyelitis optica spectrum disorder. Orphanet Journal of Rare Diseases, 2022, 17, 159.	2.7	10
3	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgGâ€“Associated Disease and Neuromyelitis Optica Spectrum Disorders. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	64
4	070â€... What is seronegative neuromyelitis optica spectrum disorder?. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A34.2-A34.	1.9	0
5	Progressive myelin oligodendrocyte glycoprotein-associated demyelination mimicking leukodystrophy. Multiple Sclerosis Journal, 2022, 28, 1481-1484.	3.0	1
6	Longitudinal Retinal Changes in <scp>MOGAD</scp>. Annals of Neurology, 2022, 92, 476-485.	5.3	20
7	Rituximab abrogates aquaporin-4â€“specific germinal center activity in patients with neuromyelitis optica spectrum disorders. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	21
8	Worldwide Incidence and Prevalence of Neuromyelitis Optica. Neurology, 2021, 96, 59-77.	1.1	101
9	Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review. Journal of Neurology, 2021, 268, 1643-1664.	3.6	18
10	Treatment of myelin oligodendrocyte glycoprotein immunoglobulinÂGâ€“associated disease. Clinical and Experimental Neuroimmunology, 2021, 12, 22-41.	1.0	9
11	No strong HLA association with MOG antibody disease in the UK population. Annals of Clinical and Translational Neurology, 2021, 8, 1502-1507.	3.7	12
12	Asian and African/Caribbean AQP4-NMOSD patient outcomes according to self-identified race and place of residence. Multiple Sclerosis and Related Disorders, 2021, 53, 103080.	2.0	7
13	Retinal Optical Coherence Tomography in Neuromyelitis Optica. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	47
14	Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurology, The, 2021, 20, 762-772.	10.2	261
15	The Role of Plasma Exchange in the Treatment of Refractory Autoimmune Neurological Diseases: a Narrative Review. Journal of NeuroImmune Pharmacology, 2021, 16, 806-817.	4.1	13
16	Predictors of relapse in MOG antibody associated disease: a cohort study. BMJ Open, 2021, 11, e055392.	1.9	30
17	Neuromyelitis optica in patients with increased interferon alpha concentrations. Lancet Neurology, The, 2020, 19, 31-33.	10.2	14
18	Common variable immunodeficiency with granulomatous-lymphocytic interstitial lung disease and preceding neurological involvement: a case-report. BMC Pulmonary Medicine, 2020, 20, 205.	2.0	5

#	Article	IF	Citations
19	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). BMJ Open, 2020, 10, e035397.	1.9	10
20	Seasonal distribution of attacks in aquaporin-4 antibody disease and myelin-oligodendrocyte antibody disease. Journal of the Neurological Sciences, 2020, 415, 116881.	0.6	10
21	Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Multiple Sclerosis and Related Disorders, 2020, 44, 102251.	2.0	110
22	Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Frontiers in Neurology, 2020, 11, 501.	2.4	216
23	Diagnostic procedures in suspected attacks in patients with neuromyelitis optica spectrum disorders: Results of an international survey. Multiple Sclerosis and Related Disorders, 2020, 41, 102027.	2.0	11
24	Neuromyelitis optica spectrum disorders. Clinical Medicine, 2019, 19, 169-176.	1.9	163
25	Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain, 2019, 142, 1310-1323.	7.6	131
26	Neurological update: MOG antibodyÂdisease. Journal of Neurology, 2019, 266, 1280-1286.	3.6	171
27	Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations. Practical Neurology, 2019, 19, 187-195.	1.1	78
28	Rituximab in neurological disease: principles, evidence and practice. Practical Neurology, 2019, 19, 5-20.	1.1	59
29	Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD. Neurology, 2018, 90, e1183-e1190.	1.1	71
30	Autoimmune encephalitis (NMDAR antibody) in a patient receiving chronic post-transplant immunosuppression. Practical Neurology, 2018, 18, 320-322.	1.1	13
31	Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease. JAMA Neurology, 2018, 75, 65.	9.0	184
32	Area postrema syndrome. Neurology, 2018, 91, e1642-e1651.	1.1	129
33	Mycophenolate for persistent complex regional pain syndrome, a parallel, open, randomised, proof of concept trial. Scandinavian Journal of Pain, 2018, 18, 29-37.	1.3	12
34	Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 132-136.	1.9	132
35	Chronic neuropathic pain severity is determined by lesion level in aquaporin 4-antibody-positive myelitis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 165-169.	1.9	37
36	Longitudinally extensive myelitis in MS mimicking neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e333.	6.0	4

#	Article	IF	Citations
37	Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e339.	6.0	32
38	Whatâ€™s new in neuromyelitis optica? A short review for the clinical neurologist. Journal of Neurology, 2017, 264, 2330-2344.	3.6	26
39	What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. Journal of Neurology, 2017, 264, 2088-2094.	3.6	168
40	Metal-Free, BrÃ¸nsted Acid-Catalyzed Formal [3+2] Annulation of Quinone Monoacetals with 2-Naphthols. Journal of Organic Chemistry, 2017, 82, 11269-11274.	3.2	23
41	AgOTf-catalyzed dehydrative [3+2] annulation of aziridines with 2-naphthols. Chemical Communications, 2017, 53, 8219-8222.	4.1	26
42	Development of a patientâ€centred conceptual framework of healthâ€related quality of life in neuromyelitis optica: a qualitative study. Health Expectations, 2017, 20, 47-58.	2.6	15
43	If they are OK, we are OK: the experience of partners living with neuromyelitis optica. Disability and Rehabilitation, 2017, 39, 1279-1286.	1.8	6
44	The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates. Multiple Sclerosis Journal, 2017, 23, 228-233.	3.0	53
45	Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain, 2017, 140, 3128-3138.	7.6	527
46	A multicentre randomiSed controlled TRial of IntraVEnous immunoglobulin compared with standard therapy for the treatment of transverse myelitis in adults and children (STRIVE). Health Technology Assessment, 2017, 21, 1-50.	2.8	20
47	Cognitive and psychiatric comorbidities in neuromyelitis optica. Journal of the Neurological Sciences, 2016, 360, 4-9.	0.6	61
48	Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes. Journal of Neurology, 2016, 263, 140-149.	3.6	60
49	Facial Onset Sensory and Motor Neuronopathy: Further Evidence for a TDP-43 Proteinopathy. Case Reports in Neurology, 2015, 7, 95-100.	0.7	30
50	Opsoclonus-myoclonus syndrome associated with a nasopharyngeal tumor in an adult: a case report. Journal of Medical Case Reports, 2015, 9, 128.	0.8	8
51	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2015, 72, 815.	9.0	59
52	Antibodies to GABA _A receptor Î±1 and Î²2 subunits. Neurology, 2015, 84, 1233-1241.	1.1	159
53	Bladder and bowel dysfunction affect quality of life. A cross sectional study of 60 patients with aquaporin-4 antibody positive Neuromyelitis Optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2015, 4, 614-618.	2.0	31
54	Solitary sclerosis: Progressive neurological deficit from a spatially isolated demyelinating lesion: A further report. Journal of Spinal Cord Medicine, 2015, 38, 551-555.	1.4	8

#	Article	IF	Citations
55	Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 470-472.	1.9	90
56	International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 2015, 85, 177-189.	1.1	3,275
57	Tonic spasms and short myelitis in an elderly womanâ€”unique onset of neuromyelitis optica. Practical Neurology, 2015, 15, 463-465.	1.1	1
58	An unusual case of 'itchy paralysisâ€™: neuromyelitis optica presenting with severe neuropathic itch. Practical Neurology, 2015, 15, 149-151.	1.1	6
59	Life on hold: the experience of living with neuromyelitis optica. Disability and Rehabilitation, 2014, 36, 1100-1107.	1.8	28
60	Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Multiple Sclerosis Journal, 2014, 20, 1533-1540.	3.0	107
61	Transverse Myelitis Associated With an Itchy Rash and HyperCKemia. JAMA Neurology, 2014, 71, 630.	9.0	18
62	Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life. Multiple Sclerosis Journal, 2014, 20, 1658-1661.	3.0	63
63	Time to next relapse as a primary endpoint in neuromyelitis optica clinical trials. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 589-590.	1.9	5
64	Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab. Journal of the Neurological Sciences, 2014, 339, 223-225.	0.6	58
65	Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Multiple Sclerosis Journal, 2014, 20, 501-504.	3.0	115
66	A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica. Autoimmunity, 2014, 47, 154-161.	2.6	109
67	The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. Journal of Neurology, 2013, 260, 2134-2137.	3.6	85
68	Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 918-921.	1.9	84
69	Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 922-930.	1.9	149
70	Neuropathic pruritus (itch) in neuromyelitis optica. Multiple Sclerosis Journal, 2013, 19, 475-479.	3.0	70
71	Does natalizumab therapy worsen neuromyelitis optica?. Neurology, 2012, 79, 1065-1066.	1.1	85
72	Genetic variations within the OPA1 gene are not associated with neuromyelitis optica. Multiple Sclerosis Journal, 2012, 18, 240-243.	3.0	1

#	Article	IF	Citations
73	Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidence. Multiple Sclerosis Journal, 2012, 18, 1801-1803.	3.0	36
74	Longitudinally extensive transverse myelitis as the sole presentation of neuro-BehÃ§et's disease responding to infliximab. Journal of Spinal Cord Medicine, 2012, 35, 122-124.	1.4	26
75	Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain, 2012, 135, 1834-1849.	7.6	361
76	A practical guide to the treatment of neuromyelitis optica. Practical Neurology, 2012, 12, 209-214.	1.1	51
77	Treatment of neuromyelitis optica: Review and recommendations. Multiple Sclerosis and Related Disorders, 2012, 1, 180-187.	2.0	217
78	Current Disease-Modifying Therapeutic Strategies in Multiple Sclerosis. Blue Books of Neurology, 2010, , 284-303.	0.1	0
79	A Case of Neuromyelitis Optica With Gadolinium-Enhancing Brain Lesions and Parinaud Syndrome. Archives of Neurology, 2009, 66, 138.	4.5	6
80	Treatment of Neuromyelitis Optica With Mycophenolate Mofetil. Archives of Neurology, 2009, 66, 1128-33.	4.5	283
81	Neuromyelitis optica - an update: 2007-2009. Annals of Indian Academy of Neurology, 2009, 12, 231.	0.5	14
82	Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle and Nerve, 2009, 39, 87-90.	2.2	123
83	Treatment of Neuromyelitis Optica With Rituximab. Archives of Neurology, 2008, 65, 1443.	4.5	445
84	Does mitochondrial DNA predispose to neuromyelitis optica (Devic's disease)?. Brain, 2008, 131, e93-e93.	7.6	17
85	Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse Myelitis. Archives of Neurology, 2008, 65, 913-9.	4.5	259
86	An Approach to the Diagnosis of Acute Transverse Myelitis. Seminars in Neurology, 2008, 28, 105-120.	1.4	210
87	Occurrence of CNS demyelinating disease in patients with myasthenia gravis. Neurology, 2007, 68, 1326-1327.	1.1	21
88	Neuromyelitis optica: Changing concepts. Journal of Neuroimmunology, 2007, 187, 126-138.	2.3	104
89	Inflammation or neoplasm? Another side to the story. Clinical Neurology and Neurosurgery, 2006, 108, 811-812.	1.4	10
90	Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis. Journal of Neurology, 2006, 253, 1160-1164.	3.6	80

#	Article	IF	Citations
91	Compression of the Deep Motor Branch of the Ulnar Nerve. Archives of Neurology, 2005, 62, 826.	4.5	9
92	Emotional facial paresis in temporal lobe epilepsy: its prevalence and lateralizing value. Seizure: the Journal of the British Epilepsy Association, 2003, 12, 60-64.	2.0	10